California Public Employees Retirement System boosted its position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 23.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,200 shares of the company’s stock after buying an additional 3,300 shares during the quarter. California Public Employees Retirement System’s holdings in Crispr Therapeutics were worth $705,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after buying an additional 268 shares during the period. NEXT Financial Group Inc increased its stake in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares in the last quarter. US Bancorp DE increased its stake in shares of Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $26,000. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $39,000. 49.82% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:CRSP opened at $67.45 on Tuesday. The firm’s 50 day moving average price is $56.78 and its 200-day moving average price is $47.86. The stock has a market capitalization of $4.00 billion, a PE ratio of -19.61 and a beta of 3.30. Crispr Therapeutics AG has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Analysts expect that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now owns 7,500 shares in the company, valued at approximately $390,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last ninety days. Insiders own 21.40% of the company’s stock.
CRSP has been the subject of a number of recent research reports. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research note on Tuesday, November 26th. BidaskClub upgraded shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 30th. Roth Capital boosted their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Friday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Buy” and an average target price of $69.54.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.